A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure

Trial Profile

A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2016

At a glance

  • Drugs Ornithine phenylacetate (Primary)
  • Indications Liver failure
  • Focus Adverse reactions
  • Acronyms STOP-ALF
  • Most Recent Events

    • 24 Oct 2016 Results published in Ocera Therapeutics media release.
    • 24 Oct 2016 According to Ocera Therapeutics media release, clinical data from this study will be presented in the late-breaking poster session at The Liver Meeting 2016, the 67th Annual Meeting of the American Association for the Study of Liver Disease (AASLD).
    • 21 Sep 2016 Status changed from recruiting to active, no longer recruiting, as per Ocera media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top